BSE Live
Mar 27, 16:01Prev. Close
1595.70
Open Price
1595.70
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Mar 27, 15:58Prev. Close
1595.60
Open Price
1595.60
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
1558.40 (12)
| Balance Sheet of Caplin Point Laboratories (in Rs. Cr.) | Jun 15 | Jun 14 | Jun 13 | Jun 12 | Jun 11 | |
| 12 mths | 12 mths | 12 mths | 12 mths | 12 mths | ||
| EQUITIES AND LIABILITIES | ||||||
| SHAREHOLDER'S FUNDS | ||||||
| Equity Share Capital | 15.11 | 15.11 | 15.11 | 15.11 | 15.11 | |
| Total Share Capital | 15.11 | 15.11 | 15.11 | 15.11 | 15.11 | |
| Reserves and Surplus | 74.79 | 43.44 | 25.05 | 15.17 | 10.49 | |
| Total Reserves and Surplus | 78.52 | 47.17 | 28.79 | 18.90 | 14.23 | |
| Total Shareholders Funds | 93.63 | 62.28 | 43.90 | 34.01 | 29.34 | |
| NON-CURRENT LIABILITIES | ||||||
| Long Term Borrowings | 0.88 | 2.02 | 3.45 | 1.55 | 0.08 | |
| Deferred Tax Liabilities [Net] | 8.69 | 7.54 | 4.79 | 2.47 | 1.53 | |
| Other Long Term Liabilities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Long Term Provisions | 0.82 | 0.81 | 0.38 | 0.27 | 0.20 | |
| Total Non-Current Liabilities | 10.39 | 10.37 | 8.62 | 4.29 | 1.82 | |
| CURRENT LIABILITIES | ||||||
| Short Term Borrowings | 0.05 | 0.05 | 0.05 | 5.20 | 9.46 | |
| Trade Payables | 38.17 | 27.45 | 22.37 | 20.35 | 16.86 | |
| Other Current Liabilities | 71.36 | 65.73 | 47.14 | 36.11 | 10.70 | |
| Short Term Provisions | 9.60 | 8.33 | 5.93 | 4.06 | 3.12 | |
| Total Current Liabilities | 119.18 | 101.56 | 75.49 | 65.72 | 40.14 | |
| Total Capital And Liabilities | 223.21 | 174.21 | 128.01 | 104.02 | 71.30 | |
| ASSETS | ||||||
| NON-CURRENT ASSETS | ||||||
| Tangible Assets | 110.88 | 99.94 | 30.81 | 25.85 | 23.21 | |
| Intangible Assets | 0.59 | 0.56 | 0.19 | 0.05 | 0.06 | |
| Capital Work-In-Progress | 30.26 | 24.87 | 51.31 | 12.79 | 0.17 | |
| Other Assets | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Fixed Assets | 142.10 | 125.47 | 82.40 | 38.68 | 23.44 | |
| Non-Current Investments | 1.44 | 0.54 | 1.29 | 1.24 | 1.20 | |
| Deferred Tax Assets [Net] | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Long Term Loans And Advances | 2.57 | 3.49 | 10.66 | 10.66 | 3.75 | |
| Other Non-Current Assets | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Total Non-Current Assets | 146.11 | 129.50 | 94.35 | 50.59 | 28.38 | |
| CURRENT ASSETS | ||||||
| Current Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Inventories | 12.66 | 7.81 | 8.92 | 5.62 | 5.16 | |
| Trade Receivables | 0.02 | 0.01 | 0.60 | 7.28 | 7.64 | |
| Cash And Cash Equivalents | 40.32 | 23.17 | 13.45 | 27.61 | 21.57 | |
| Short Term Loans And Advances | 22.90 | 12.69 | 10.10 | 11.74 | 8.11 | |
| OtherCurrentAssets | 1.20 | 1.04 | 0.59 | 1.18 | 0.44 | |
| Total Current Assets | 77.10 | 44.71 | 33.67 | 53.43 | 42.92 | |
| Total Assets | 223.21 | 174.21 | 128.01 | 104.02 | 71.30 | |
| OTHER ADDITIONAL INFORMATION | ||||||
| CONTINGENT LIABILITIES, COMMITMENTS | ||||||
| Contingent Liabilities | 10.20 | 20.03 | 22.63 | 4.20 | 2.72 | |
| CIF VALUE OF IMPORTS | ||||||
| Raw Materials | 69.01 | 56.67 | 42.83 | 38.06 | 34.46 | |
| Stores, Spares And Loose Tools | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Trade/Other Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Capital Goods | 4.10 | 1.31 | 5.05 | 3.91 | 0.83 | |
| EXPENDITURE IN FOREIGN EXCHANGE | ||||||
| Expenditure In Foreign Currency | 2.13 | 1.79 | 1.21 | 1.17 | 0.94 | |
| REMITTANCES IN FOREIGN CURRENCIES FOR DIVIDENDS | ||||||
| Dividend Remittance In Foreign Currency | 0.05 | 0.03 | 0.03 | 0.02 | 0.02 | |
| EARNINGS IN FOREIGN EXCHANGE | ||||||
| FOB Value Of Goods | 220.17 | 151.02 | 108.47 | 89.74 | 69.53 | |
| Other Earnings | -- | -- | -- | -- | -- | |
| BONUS DETAILS | ||||||
| Bonus Equity Share Capital | -- | -- | -- | -- | -- | |
| NON-CURRENT INVESTMENTS | ||||||
| Non-Current Investments Quoted Market Value | -- | -- | -- | -- | -- | |
| Non-Current Investments Unquoted Book Value | 1.37 | 0.47 | 1.24 | 1.19 | 1.14 | |
| CURRENT INVESTMENTS | ||||||
| Current Investments Quoted Market Value | -- | -- | -- | -- | -- | |
| Current Investments Unquoted Book Value | -- | -- | -- | -- | -- |
10.02.2026
Caplin Labs Consolidated December 2025 Net Sales at Rs 542.77 crore, up 10.1% Y-o-Y
09.02.2026
Caplin Labs Standalone December 2025 Net Sales at Rs 189.22 crore, up 2.15% Y-o-Y
12.11.2025
Caplin Labs Standalone September 2025 Net Sales at Rs 175.18 crore, down 15.75% Y-o-Y
05.11.2025
Caplin Labs Consolidated September 2025 Net Sales at Rs 534.04 crore, up 10.54% Y-o-Y
27.03.2026
After Biologics merger, new CEO Shreehas Tambe recasts Biocon as global medicines player
27.03.2026
27.03.2026
26.03.2026
As Strides Pharma stabilises balance sheet, focus shifts to growth beyond the US
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
12.11.2025
07.11.2025
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
17.07.2025
Sun Pharma Q1 PAT seen up 8.4% YoY to Rs 3,132.7 cr: ICICI Securities
17.07.2025
Biocon Q1 PAT may dip 72% YoY to Rs 91.1 cr: ICICI Securities
17.07.2025
Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities
29.01.2025
Sun Pharma Q3 Preview: Double-digit India, US sales to power mid-teen profit growth